2025年核子医学诊断全球市场报告

近年来，核子医学诊断市场规模迅速扩张，从2024年的71.6亿美元成长到2025年的78.8亿美元，复合年增长率达10.2%。这段历史时期的成长可归因于医学影像技术的进步、慢性病盛行率的上升、人口老化趋势、肿瘤学临床应用以及诊断精度和准确度的提高。

预计未来几年核医诊断市场将快速成长，到2029年将达到123.8亿美元，年复合成长率（CAGR）为11.9%。预测期内的成长归因于神经病学应用的不断扩展、与其他显像模式的整合、精准医疗方法、对治疗诊断学日益增长的需求以及全球根除疾病的努力。预测期内的主要趋势包括向小型分散式放射性药物药房的转变、核医学在神经病学中的应用、放射组学和定量成像分析、研发合作以及对辐射安全和剂量测定的日益关注。

核子医学利用放射性物质注入体内来诊断疾病，或在治疗过程中选择性地靶向并切除患病或受损的器官或组织。该领域涵盖将放射性药物用于研究、治疗和诊断目的。诊断性核子医学使用放射性示踪剂来观察和/或测量特定器官的整体或局部功能，为医学诊断和治疗计划提供宝贵的见解。

核子医学诊断的主要类别包括SPECT放射性药物和PET放射性药物。 SPECT放射性药物（单光子发射电脑断层扫描）与核子医学领域使用的伽马射线断层扫描技术相关。这些方法可应用于心臟病学、甲状腺学、神经病学和肿瘤学等多个医学领域。这些诊断技术的最终用户包括医院、诊断中心和研究机构。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要医疗设备重新认证，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供您在核医学诊断行业取得成功所需的数据，涵盖核医学诊断市场统计数据，例如全球市场规模、区域份额、核医学诊断市场份额的竞争对手、详细的核医学诊断细分市场、市场趋势和商业机会。这份核子医学诊断市场研究报告透过对产业现状和未来趋势的详细分析，全面展望了您所需的一切。

未来五年的预测成长率为11.9%，较我们先前对该市场的预测略有下降0.2%。这一下降主要源自于美国与其他国家之间关税的影响。此影响可能直接影响美国，包括对比利时锗-68/镓-68发生器的关税上调、聚对苯二甲酸乙二醇酯(PET)放射性药物成本上升，以及可能限制获得晚期癌症分期方法。此外，互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响也将对美国产生更广泛的影响。

由于对这种诊断技术的需求不断增长，核医学诊断市场预计将成长。核子医学利用体内的放射性物质来诊断疾病，并在治疗过程中瞄准和切除患病或受损的器官和组织。核子医学诊断的主要用途是放射治疗和其他挽救生命的治疗。由于此类诊断具有许多好处，包括准确的结果和改进的治疗决策能力，对此类诊断的需求正在增加。根据倡导核能发电的英国国际组织世界核能协会 2022 年 4 月报道，核子医学治疗的数量每年将超过 4,000 万次，放射性同位素的需求每年以高达 5% 的速度成长。值得注意的是，全球 90% 以上的涉及放射性同位素的医疗程序是在全球 10,000 多家医院进行的。需求的激增凸显了核医学诊断的关键作用，并有助于核医诊断市场的预期成长。

预计癌症发生率的上升将在未来几年推动核医学诊断市场的成长。癌症是指一系列以异常细胞不受控制地生长和扩散为特征的疾病，导致肿瘤的形成。核子医学诊断利用可被特殊相机识别的放射性物质生成器官和组织内部结构和功能的详细影像，在各种癌症的检测、分期和监测中发挥关键作用。例如，2023年1月，美国政府间组织国家生物技术资讯中心报告称，当年美国新增癌症病例数为1,958,310例，癌症相关死亡人数为609,820例。因此，癌症患者数量的增加正在刺激核医诊断市场的扩张。

核子医学诊断市场的主要企业正策略性地专注于采用先进的解决方案，尤其是先进的医疗技术，以建立竞争优势。先进的医疗技术是指医疗领域的尖端创新，旨在改善患者的治疗效果、提高护理水平并促进整体健康。马来西亚医疗保健服务提供者鹰阁医院就是一个例子。 2023 年 8 月，该医院引入了核子医学治疗室，展示了对先进医疗技术的承诺。该专科病房配备了尖端技术并配备了熟练的专业人员，旨在透过核子医学扫描术诊断技术促进疾病的早期发现、诊断和治疗。领先公司的此类努力凸显了该行业致力于技术进步和提高核医学诊断市场的医疗能力。

核子医学诊断市场包括肾臟扫描、骨骼扫描、镓扫描、心臟扫描、脑部扫描和乳房扫描的销售。该市场的价值是“出厂价”，即商品製造商或创造者出售给其他营业单位（包括下游製造商、经销商、分销商和零售商）或直接出售给最终客户的商品价值。该市场中的商品价值还包括商品创造者出售的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第 4 章 - 市场 - 宏观经济情境宏观经济情境包括利率、通货膨胀、地缘政治、贸易战和关税，以及 COVID-19 大流行和復苏对市场的影响。

第五章 全球成长分析与策略分析框架

• 全球核子医学诊断：PESTEL分析（政治、社会、科技、环境、法律因素、驱动因素与限制因素）
• 最终用途产业分析
• 全球核子医学诊断市场：成长率分析
• 全球核子医学诊断市场表现：规模与成长，2019-2024
• 全球核子医学诊断市场预测：规模与成长，2024-2029年，2034年
• 全球核子医学诊断：总目标市场（TAM）

第六章 市场细分

• 全球核子医学诊断市场：依类型、绩效与预测，2019-2024 年、2024-2029 年、2034 年
• SPECT放射性药物
• PET放射性药物
• 全球核子医学诊断市场：应用、绩效及预测（2019-2024年、2024-2029年、2034年）
• 心臟病学
• 甲状腺
• 神经病学
• 肿瘤学
• 其他用途
• 全球核子医学诊断市场：按最终用户、绩效和预测，2019-2024 年、2024-2029 年、2034 年
• 医院和诊断中心
• 研究机构
• 全球核子医学诊断市场：依 SPECT 放射性药物类型细分、绩效及预测（2019-2024 年、2024-2029 年、2034 年）
• Technetium-99m放射性药物
• 碘-123放射性药物
• 铊-201放射性药物
• 其他 SPECT 放射性药物
• 全球核子医学诊断市场：PET放射性药物细分（按类型）、绩效及预测，2019-2024年、2024-2029年、2034年
• 氟-18放射性药物
• 碳-11放射性药物
• 镓-68基放射性药物
• 其他PET放射性药物

第七章 区域和国家分析

• 全球核子医学诊断市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 全球核子医学诊断市场：依国家、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

• 核子医学诊断市场：竞争格局
• 核子医学诊断市场：公司简介
  • Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

• Mallinckrodt Pharmaceuticals
• Bracco Diagnostics Inc.
• Lantheus Holdings Inc.
• IBA Radiopharma Solutions
• Curium SAS
• Cardinal Health Inc.
• Eckert & Ziegler Strahlen-und Medizintechnik AG
• Advanced Accelerator Applications
• Telix Pharmaceuticals Limited
• Nordion（Canada）Inc.
• NorthStar Medical Technologies LLC
• SHINE Medical Technologies LLC
• Navidea Biopharmaceuticals Inc.
• Cyclopharm Limited
• Isologic Innovative Radiopharmaceuticals

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

• 2029年核子医学诊断市场：提供新机会的国家
• 2029年核子医学诊断市场：细分领域带来新机会
• 2029年核子医学诊断市场：成长策略
  • 基于市场趋势的策略
  • 竞争对手策略

第36章 附录

Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.

The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $7.16 billion in 2024 to $7.88 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to advancements in medical imaging, increasing prevalence of chronic diseases, aging population trends, clinical applications in oncology, diagnostic accuracy and precision.

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $12.38 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expanding applications in neurology, integration with other imaging modalities, precision medicine approaches, rising demand for theranostics, global efforts in disease eradication. Major trends in the forecast period include shift towards small-scale, decentralized radiopharmacy, application of nuclear medicine in neurology, radiomics and quantitative imaging analysis, collaborations for research and development, emphasis on radiation safety and dosimetry.

The forecast of 11.9% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through increased duties on germanium-68/gallium-68 generators from Belgium, raising costs for polyethylene terephthalate (PET) radiopharmaceuticals and potentially limiting access to advanced cancer staging procedures.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the nuclear medicine diagnostics market is driven by a rising demand for these diagnostic techniques. Nuclear medicine utilizes radioactive substances within the body for diagnosing illnesses and for targeted removal of diseased or damaged organs and tissues during treatment. The applications of nuclear medicine diagnostics are predominantly in radiation and other life-saving treatments. The increasing demand for these diagnostics is attributed to their advantages, including accurate results and enhanced treatment decision-making capabilities. As reported in April 2022 by the World Nuclear Association, a UK-based international organization advocating for nuclear power, the annual number of nuclear medicine treatments surpasses 40 million, with the demand for radioisotopes witnessing a yearly growth rate of up to 5%. Notably, over 90% of procedures involving radioisotopes in medicine are conducted in more than 10,000 hospitals worldwide. This surge in demand underscores the pivotal role of nuclear medicine diagnostics, contributing to the anticipated growth of the nuclear medicine diagnostics market.

The increasing incidence of cancer is anticipated to drive the growth of the nuclear medicine diagnostics market in the coming years. Cancer refers to a collection of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, which can lead to the formation of tumors. Nuclear medicine diagnostics plays a crucial role in detecting, staging, and monitoring various cancer types by using radioactive substances that can be identified by specialized cameras, producing detailed images of the internal structures and functions of organs and tissues. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported that there were 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States that year. Thus, the rising number of cancer cases is fueling the expansion of the nuclear medicine diagnostics market.

Prominent companies in the nuclear medicine diagnostics market are strategically focusing on the introduction of advanced solutions, particularly advanced medical technologies, to establish a competitive advantage. Advanced medical technologies represent cutting-edge innovations within the medical field, aimed at improving patient outcomes, elevating the standard of care, and fostering overall health improvement. An illustrative example is Gleneagles Hospital, a Malaysia-based company providing medical and healthcare services. In August 2023, the hospital introduced a Nuclear Medicine Unit, showcasing its commitment to advanced medical technologies. This specialized unit, equipped with state-of-the-art technology and staffed by highly skilled professionals, is designed to facilitate early detection, diagnosis, and treatment of diseases through nuclear medicine imaging techniques. Such initiatives by major companies underscore the industry's dedication to advancing technology and enhancing medical capabilities within the nuclear medicine diagnostics market.

Major companies in the nuclear medicine diagnostics market are actively pursuing strategic partnerships as a key approach to securing a competitive edge. Strategic partnerships involve collaborative efforts between two or more entities with the goal of achieving mutually advantageous objectives by combining resources and expertise. A noteworthy example occurred in June 2023, where RLS Inc., a US-based nuclear medicine provider, entered into a strategic partnership with SOFIE, a US-based molecular imaging company. Through this collaboration, RLS Inc. aims to enhance the distribution of nuclear medicine doses to patients, hospitals, teaching institutions, and doctors, thereby improving the overall continuum of care for patients. This strategic partnership will streamline patient dose preparation, capitalizing on the accredited radiopharmacy network and expertise of both entities involved. Such initiatives underscore the industry's commitment to fostering collaboration and leveraging collective strengths to drive advancements in the nuclear medicine diagnostics market.

In January 2022, Eckert & Ziegler, a Germany-based provider of isotope technology for medical, scientific, and industrial applications, successfully acquired Tecnonuclear SA for an undisclosed sum. This strategic acquisition positions Eckert & Ziegler to broaden its footprint and enhance essential healthcare services in Brazil and across South America. Tecnonuclear SA, an Argentina-based specialist in nuclear medicine, brings valuable expertise and resources to strengthen Eckert & Ziegler's presence in the region, aligning with the company's commitment to advancing isotope technology for medical applications.

Major companies operating in the nuclear medicine diagnostics market include Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Cardinal Health Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Global Medical Solutions LLC, Theragnostics Ltd., EczacIbasI-Monrol Nuclear Products Co.

North America was the largest region in the nuclear medicine diagnostics market in 2024. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals
• 2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
• 3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
• Subsegments:
• 1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals; Iodine-123-Based Radiopharmaceuticals; Thallium-201-Based Radiopharmaceuticals; Other SPECT Radiopharmaceuticals
• 2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals; Carbon-11-Based Radiopharmaceuticals; Gallium-68-Based Radiopharmaceuticals; Other PET Radiopharmaceuticals
• Companies Mentioned: Siemens AG; Bayer Aktiengesellschaft; Novartis AG; GE Healthcare Technologies Inc.; Perkin Elmer Inc.; Mallinckrodt Pharmaceuticals; Bracco Diagnostics Inc.; Lantheus Holdings Inc.; IBA Radiopharma Solutions; Curium SAS; Cardinal Health Inc.; Eckert & Ziegler Strahlen- und Medizintechnik AG; Advanced Accelerator Applications; Telix Pharmaceuticals Limited; Nordion (Canada) Inc.; NorthStar Medical Technologies LLC; SHINE Medical Technologies LLC; Navidea Biopharmaceuticals Inc.; Cyclopharm Limited; Isologic Innovative Radiopharmaceuticals; Clarity Pharmaceuticals Limited; Actinium Pharmaceuticals Inc.; Jubilant DraxImage Inc.; PharmaLogic Holdings Corp; Institute of Isotopes Co Ltd.; Global Medical Solutions LLC; Theragnostics Ltd.; EczacIbasI-Monrol Nuclear Products Co.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nuclear Medicine Diagnostics Market Characteristics

3. Nuclear Medicine Diagnostics Market Trends And Strategies

4. Nuclear Medicine Diagnostics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Nuclear Medicine Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nuclear Medicine Diagnostics Market Growth Rate Analysis
• 5.4. Global Nuclear Medicine Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nuclear Medicine Diagnostics Total Addressable Market (TAM)

6. Nuclear Medicine Diagnostics Market Segmentation

• 6.1. Global Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SPECT Radiopharmaceuticals
• PET Radiopharmaceuticals
• 6.2. Global Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiology
• Thyroid
• Neurology
• Oncology
• Other Applications
• 6.3. Global Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Diagnostic Centers
• Research Institutes
• 6.4. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of SPECT Radiopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Technetium-99m-Based Radiopharmaceuticals
• Iodine-123-Based Radiopharmaceuticals
• Thallium-201-Based Radiopharmaceuticals
• Other SPECT Radiopharmaceuticals
• 6.5. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of PET Radiopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluorine-18-Based Radiopharmaceuticals
• Carbon-11-Based Radiopharmaceuticals
• Gallium-68-Based Radiopharmaceuticals
• Other PET Radiopharmaceuticals

7. Nuclear Medicine Diagnostics Market Regional And Country Analysis

• 7.1. Global Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nuclear Medicine Diagnostics Market

• 8.1. Asia-Pacific Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nuclear Medicine Diagnostics Market

• 9.1. China Nuclear Medicine Diagnostics Market Overview
• 9.2. China Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nuclear Medicine Diagnostics Market

• 10.1. India Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nuclear Medicine Diagnostics Market

• 11.1. Japan Nuclear Medicine Diagnostics Market Overview
• 11.2. Japan Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nuclear Medicine Diagnostics Market

• 12.1. Australia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nuclear Medicine Diagnostics Market

• 13.1. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nuclear Medicine Diagnostics Market

• 14.1. South Korea Nuclear Medicine Diagnostics Market Overview
• 14.2. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nuclear Medicine Diagnostics Market

• 15.1. Western Europe Nuclear Medicine Diagnostics Market Overview
• 15.2. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nuclear Medicine Diagnostics Market

• 16.1. UK Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nuclear Medicine Diagnostics Market

• 17.1. Germany Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nuclear Medicine Diagnostics Market

• 18.1. France Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nuclear Medicine Diagnostics Market

• 19.1. Italy Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nuclear Medicine Diagnostics Market

• 20.1. Spain Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nuclear Medicine Diagnostics Market

• 21.1. Eastern Europe Nuclear Medicine Diagnostics Market Overview
• 21.2. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nuclear Medicine Diagnostics Market

• 22.1. Russia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nuclear Medicine Diagnostics Market

• 23.1. North America Nuclear Medicine Diagnostics Market Overview
• 23.2. North America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nuclear Medicine Diagnostics Market

• 24.1. USA Nuclear Medicine Diagnostics Market Overview
• 24.2. USA Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nuclear Medicine Diagnostics Market

• 25.1. Canada Nuclear Medicine Diagnostics Market Overview
• 25.2. Canada Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nuclear Medicine Diagnostics Market

• 26.1. South America Nuclear Medicine Diagnostics Market Overview
• 26.2. South America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nuclear Medicine Diagnostics Market

• 27.1. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nuclear Medicine Diagnostics Market

• 28.1. Middle East Nuclear Medicine Diagnostics Market Overview
• 28.2. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nuclear Medicine Diagnostics Market

• 29.1. Africa Nuclear Medicine Diagnostics Market Overview
• 29.2. Africa Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Nuclear Medicine Diagnostics Market Competitive Landscape
• 30.2. Nuclear Medicine Diagnostics Market Company Profiles
  • 30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

• 31.1. Mallinckrodt Pharmaceuticals
• 31.2. Bracco Diagnostics Inc.
• 31.3. Lantheus Holdings Inc.
• 31.4. IBA Radiopharma Solutions
• 31.5. Curium SAS
• 31.6. Cardinal Health Inc.
• 31.7. Eckert & Ziegler Strahlen- und Medizintechnik AG
• 31.8. Advanced Accelerator Applications
• 31.9. Telix Pharmaceuticals Limited
• 31.10. Nordion (Canada) Inc.
• 31.11. NorthStar Medical Technologies LLC
• 31.12. SHINE Medical Technologies LLC
• 31.13. Navidea Biopharmaceuticals Inc.
• 31.14. Cyclopharm Limited
• 31.15. Isologic Innovative Radiopharmaceuticals

32. Global Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market

34. Recent Developments In The Nuclear Medicine Diagnostics Market

35. Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Nuclear Medicine Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nuclear Medicine Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nuclear Medicine Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer